Latest Becton Dickinson Stories
First drug approved for launch in BD Simplist(TM) family of products FRANKLIN LAKES, N.J., March 27, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first drug to be offered in the just-launched BD Simplist(TM) ready-to-administer, line of prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and...
FRANKLIN LAKES, N.J., March 13, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company's Management Committee...
Offers comprehensive pharmacy workflow solution FRANKLIN LAKES, N.J., March 12, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Cato Software Solutions, the manufacturer of cato® and chemocato® software, a suite of comprehensive medication safety solutions for pharmacy intravenous medication preparation, physician therapy planning and nurse bedside documentation. Cato Software...
FRANKLIN LAKES, N.J., Feb. 28, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in March 2013: Cowen and Company 33(rd) Annual Healthcare ConferenceMarch 4, 20131:30 p.m. ET Raymond James 34(th) Annual Institutional Investors ConferenceMarch 5, 20132:50 p.m. ET Barclays Global Healthcare ConferenceMarch 13, 201310:45 a.m. ET Live...
Blood Culture Systems Comparison Study Shows BD BACTEC(TM) Plus Aerobic Medium Provides Statistically Significant Differences in Bacterial Recovery for Patients on Antimicrobial Therapy BALTIMORE, Feb. 28, 2013 /PRNewswire/ -- A new study, published in the journal Clinical Infectious Diseases, demonstrates how treatment with broad-spectrum antibiotics can impact the ability to detect bacteria in blood samples from potentially septic patients. It also highlights the importance of...
“Patient Examination Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018”, “Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018” and “Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018” new market research reports added to ReportsnReports.com store. Dallas, Texas (PRWEB) February 22, 2013 These reports on BRICS...
NEW YORK, February 21, 2013 /PRNewswire/ -- Today, National Traders Association announced new research reports highlighting Bruker Corporation (NASDAQ: BRKR), Agilent Technologies Inc. (NYSE: A), General Electric Company (NYSE: GE), Becton, Dickinson and Co. (NYSE: BDX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Bruker...
FRANKLIN LAKES, N.J., Feb. 7, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following investor healthcare conferences in February 2013: Leerink Swann Global Healthcare Conference 2013February 14, 20132:00 p.m. ET 2013 Citi Global Healthcare ConferenceFebruary 26, 20138:00 a.m. ET 2013 RBC Capital Markets' Healthcare ConferenceFebruary 27, 201311:30 a.m. ET Live webcasts...
FRANKLIN LAKES, N.J., Feb. 5, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.90 billion for the first fiscal quarter ended December 31, 2012, representing an increase of 3.7 percent from the prior-year period, or 5.2 percent on a foreign currency-neutral basis. "We are very pleased with our start to fiscal year 2013," said Vincent A. Forlenza, Chairman, Chief Executive...
FRANKLIN LAKES, N.J., Jan. 29, 2013 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 49.5 cents per common share, payable on March 29, 2013 to holders of record on March 8, 2013. The indicated annual dividend rate is $1.98 per share. About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to...
